-
Study aim
-
This study compares the effect of adding dexmedetomidine versus sufentanil as adjuvants to epidural ropivacaine on labor analgesia quality, maternal hemodynamics, labor duration, cesarean rate, and neonatal outcomes in primigravid women
-
Design
-
A phase III, double-blind randomized controlled trial with parallel groups conducted on 104 pregnant women candidates for epidural labor analgesia. Participants are allocated into two equal groups of 52 (ropivacaine + sufentanil vs. ropivacaine + dexmedetomidine). Randomization is performed using permuted blocks of four generated via Excel RAND function and concealed in sequentially numbered sealed envelopes.
-
Settings and conduct
-
This phase III, double-blind randomized controlled trial with parallel groups enrolls 104 participants at Taleghani Hospital, Arak. Randomization uses permuted blocks of four via Excel RAND function with sealed envelopes. Blinding is maintained through identical unlabeled syringes prepared by an independent anesthesiologist
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria include primigravid women with singleton pregnancies candidates for epidural labor analgesia, written informed consent, and no contraindication to epidural anesthesia. Exclusion criteria Hypersensitivity to drugs, contraindication to epidural, multiple gestation, multiparity, abnormal fetal presentation, cervical dilation >8 cm, uncontrolled systemic disease, psychiatric disorder or addiction, and history of lumbar spine surgery
-
Intervention groups
-
Group I : ropivacaine 0.1% + sufentanil 0.25 µg/mL (total 20 µg), 10 mL epidural bolus. Group II : ropivacaine 0.1% + dexmedetomidine 0.1 µg/kg, 10 mL epidural bolus.
-
Main outcome variables
-
Primary outcomes include pain intensity (VAS) at baseline, 5, 15, 30, and 60 minutes post-injection, analgesia duration, and neonatal Apgar scores at 1 and 5 minutes.